This page lists the SEC filings reported by Laurion Capital Management LP.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2024-02-08 | Laurion Capital Management LP | Biomea Fusion, Inc. | 2,736,367 | 7.7% | EDGAR |
| SC 13G | 2024-02-08 | Laurion Capital Management LP | PLIANT THERAPEUTICS, INC. | 3,583,567 | 6.0% | EDGAR |
| SC 13G/A | 2023-03-03 | Laurion Capital Management LP | Codiak BioSciences, Inc. | 3,713,300 | 9.6% | EDGAR |
| SC 13G/A | 2023-02-08 | Laurion Capital Management LP | Research Alliance Corp. II | - | 0.0% | EDGAR |
| SC 13G | 2023-02-08 | Laurion Capital Management LP | Codiak BioSciences, Inc. | 2,013,300 | 5.5% | EDGAR |
| SC 13G | 2023-02-08 | Laurion Capital Management LP | Pyxis Oncology, Inc. | 3,170,803 | 9.0% | EDGAR |
| SC 13G | 2022-02-01 | Laurion Capital Management LP | Research Alliance Corp. II | 800,000 | 5.2% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.